The supplemental new drug application (sNDA) for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD) has been accepted and filed by the ...
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc., (OAPI) and Otsuka Pharmaceutical, Co., Ltd. (Otsuka) announce that the U.S. Food and Drug Administration (FDA) plans to ...
(RTTNews) - The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.
The FDA is raising efficacy questions over Lundbeck and Otsuka’s proposed combination of their Rexulti with Viatris’ Zoloft as a treatment for post-traumatic stress disorder (PTSD). For an upcoming ...
With an FDA advisory committee recommendation in hand, Lundbeck and Otsuka’s Rexulti is one step closer to locking down a new indication in Alzheimer’s disease related agitation. In a 9-1 vote on ...
The FDA will hold a joint meeting of its expert advisors to determine whether the drug Rexulti (brexpiprazole) is appropriate for use in treating agitation associated with Alzheimer’s disease dementia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results